Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- PeptiDream-Shionogi-Sekisui Trio to Launch Peptide Therapeutics CMO in September
August 8, 2017
- Pfizer Recalls Wypax Tablets in Japan
August 7, 2017
- Sumitomo Dainippon Drops Napabucasin for Stomach Cancer, but Maintains 100 Billion Yen Target
August 7, 2017
- Takeda, Molecular Templates Join Hands on Cancer Therapies
August 7, 2017
- Takeda Forms R&D Partnership with Cardurion for Cardiovascular Diseases
August 4, 2017
- Partial Modification of Approval for Asacol Generics Eliminates Discrepancy in Indications
August 4, 2017
- Japan Ethical Drug Sales in April-June Down 0.8%, with Harvoni Sales Down 75.6%: QuintilesIMS
August 4, 2017
- LTL Pharma to Take Over 3 Brands from Astellas in October
August 3, 2017
- Meiji Seika Pharma to Transfer 3 Generic Brands to Its Generic Subsidiary
August 3, 2017
- Galderma Transfers Epiduo Gel to Maruho in Japan
August 3, 2017
- 3 Deaths among 85 ADRs Bayer Yakuhin Failed to Report Were Known to Employees at Symposiums
August 3, 2017
- Daiichi Sankyo Inks US$300 Million Settlement Deal over Olmesartan Product Liability Litigation in US
August 3, 2017
- Abilify Maintena Approved for Bipolar I Disorder in US
August 2, 2017
- Astellas Applies for Fidaxomicin for Infectious Enteritis in Japan
August 2, 2017
- Biotech Startup Begins Operations in Takeda’s Shonan Research Center
August 2, 2017
- Bayer Yakuhin Finds 85 Further Cases of Unreported ADRs
August 2, 2017
- No Policy Change in Obtaining Regulatory Approval of Nesp Biosimilar through New Firm: Kyowa Kirin President
August 1, 2017
- August FDA Filing Planned for FGF23 Antibody Burosumab: Kyowa Kirin
July 31, 2017
- Abilify-Jzoloft Combo Filed in Japan: Otsuka
July 31, 2017
- Kyowa Kirin Enjoys Higher Earnings on Benralizumab License Revenue
July 31, 2017
ページ
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…